Indicators of hemostasis and fibrinolysis systems and systemic inflammatory response in patients with newly diagnosed sarcoidosis after COVID-19

DOI: https://doi.org/10.29296/25877305-2023-12-08
Issue: 
12
Year: 
2023

Professor R. Abdullaev(1), MD; V. Shorokhova(1), Candidate of Medical Sciences;
N. Makaryants(1), MD; O. Komissarova(1, 2), MD
1-Central Research Institute of Tuberculosis, Moscow
2-N.I. Pirogov National Research Medical University, Ministry of Health of Russia, Moscow

Objective. To study the indicators of hemostasis and fibrinolysis systems, as well as the systemic inflammatory response in patients with newly diagnosed sarcoidosis after infection caused by SARS-CoV-2. Material and methods. A prospective analysis of the indicators of hemostasis and fibrinolysis systems, as well as the systemic inflammatory response of 20 patients with sarcoidosis, after COVID-19, who were on inpatient treatment in Central TB Research Institute. The patients were divided into 2 groups. The first group included 10 patients with sarcoidosis, who had suffered COVID-19 (the main group). The comparison group consisted of 10 patients with sarcoidosis without a history of COVID-19. Results. It was found, that in patients with newly diagnosed sarcoidosis, who underwent COVID-19, there is a hypercoagulation shift in the hemostasis and fibrinolysis system. This was evidenced by a significant shortening of the indicators of APTT, PT and an increase in the level of D-dimer compared to both healthy and patients, who had not undergone COVID-19. In addition, laboratory manifestations of systemic inflammation were most pronounced in patients with sarcoidosis who underwent COVID-19. Probably, changes in the hemostasis and fibrinolysis system occurred within the framework of a systemic inflammatory response.
Keywords: 
tuberculosis
COVID-19
systemic inflammatory response
hemostasis and fibrinolysis system.

References: 
  1. Абдуллаев Р.Ю., Комиссарова О.Г. Лабораторные проявления короновирусной инфекции COVID-19. Врач. 2020; 31 (5): 3–6 [Abdullaev R., Komissarova O. Laboratory indicators of coronаvirus infection COVID-19. Vrach. 2020; 31 (5): 3–6. (in Russ.)]. DOI: 10.29296/25877305-2020-05-01
  2. Бородулина Е.А., Широбоков Я.Е., Гладунова Е.П. и др. Диагностика и фармакотерапия вирус-ассоциированных поражений легких. Клиническая фармакология и терапия. 2020; 29 (3): 61–6 [Borodulina E.A., Shirobokov Y.E., Gladunova E.P. et al. Virus-associated lung disease. Clin Pharmacol Ther. 2020; 29 (3): 61–6 (in Russ.)]. DOI: 10.32756/0869-5490-2020-3-61-66
  3. Визель А.А., Визель И.Ю., Амиров Н.Б. Эпидемиология саркоидоза в Российской Федерации. Вестник современной клинической медицины. 2017; 10 (5): 66–73 [Vizel А.А., Vizel I.Yu., Amirov N.B. Epidemiology of sarcoidosis in the Russian Federation. The Bulletin of Contemporary Clinical Medicine. 2017; 10 (5): 66–73 (in Russ.)]. DOI: 10.20969/VSKM.2017.10(5).66-73
  4. Старшинова А.А., Малкова А.М., Зинченко Ю.С. и др. Аутоиммунная составляющая в этиологии саркоидоза. Туберкулез и болезни легких. 2020; 98(5): 54–62 [Starshinova A.A., Malkova A.M., Zinchenko Yu.S., et al. Autoimmune component in the etiology of sarcoidosis. Tuberculosis and Lung Diseases. 2020; 98 (5): 54–62 (in Russ.)]. DOI: 10.21292/2075-1230-2020-98-5-54-62
  5. Brito-Zerón P., Gracia-Tello B., Robles A. et al. Characterization and Outcomes of SARS-CoV-2 Infection in Patients with Sarcoidosis. Viruses. 2021; 13 (6): 1000. DOI: 10.3390/v13061000
  6. Brito-Zerón P., Pérez-Álvarez R., Ramos-Casals M. Sarcoidosis. Med Clin (Barc). 2022; 159 (4):195–204. DOI: 10.1016/j.medcli.2022.03.009
  7. Capaccione K.M., McGroder C., Garcia C. K. et al. COVID-19-induced pulmonary sarcoid: A case report and review of the literature. Clin Imaging. 2022; 83: 152–8. DOI: 10.1016/j.clinimag.2021.12.021
  8. Hadi Y.B., Lakhani D.A., Naqvi S.F.Z. et al. Outcomes of SARS-CoV-2 infection in patients with pulmonary sarcoidosis: A multicenter retrospective research network study. Respir Med. 2021; 187: 106538. DOI: 10.1016/j.rmed.2021.106538
  9. Kahlmann V., Manansala M., Moor C.C. et al. COVID-19 infection in patients with sarcoidosis: susceptibility and clinical outcomes. Curr Opin Pulm Med. 2021; 27 (5): 463–71. DOI: 10.1097/MCP.0000000000000812
  10. Palones E., Pajares V., Lopez L. et al. Sarcoidosis following SARS-CoV-2 infection: Cause or consequence. Respirol Case Rep. 2022; 10 (6): e0955. DOI: 10.1002/rcr2.955
  11. Rabufetti A., Borradori L., Heidemeyer K. et al. New onset of sarcoidosis after COVID-19 infection. J Eur Acad Dermatol Venereol. 2022; 36 (10): e756-e759. DOI: 10.1111/jdv.18313
  12. Rossides M., Darlington P., Kullberg S. et al. Sarcoidosis: Epidemiology and clinical insights. J Intern Med. 2023; 293 (6): 668–80. DOI: 10.1111/joim.13629
  13. Starshinova A., Zinchenko Y., Malkova A. et al. Sarcoidosis and Autoimmune Inflammatory Syndrome Induced by Adjuvants. Life (Basel). 2023; 13 (4): 1047. DOI: 10.3390/life13041047
  14. Strangfeld A., Schafer M., Gianfrancesco M.A. et al. Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2021; 80 (7): 930–42. DOI: 10.1136/annrheumdis-2020-219498
  15. Tang N., Li D., Wang X., et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18 (4): 844–7. DOI: 10.1111/jth.14768